XTRA:FYB

Stock Analysis Report

Executive Summary

Formycon AG engages in the development and marketing of biosimilar products.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Formycon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

FYB

-0.01%

DE Biotechs

4.1%

DE Market


1 Year Return

9.1%

FYB

3.1%

DE Biotechs

2.4%

DE Market

Return vs Industry: FYB exceeded the German Biotechs industry which returned 3.1% over the past year.

Return vs Market: FYB exceeded the German Market which returned 2.4% over the past year.


Shareholder returns

FYBIndustryMarket
7 Day1.5%-0.01%4.1%
30 Day13.2%-3.9%1.7%
90 Day7.9%-3.2%3.7%
1 Year9.1%9.1%3.3%3.1%5.6%2.4%
3 Year77.2%77.2%69.5%67.9%19.2%8.9%
5 Year339.4%339.4%17.3%14.7%43.2%23.7%

Price Volatility Vs. Market

How volatile is Formycon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Formycon undervalued compared to its fair value and its price relative to the market?

6.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate FYB's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate FYB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FYB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FYB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate FYB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FYB is overvalued based on its PB Ratio (6.9x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Formycon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-65.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FYB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FYB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FYB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FYB's revenue (28.5% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: FYB's revenue (28.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if FYB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Formycon performed over the past 5 years?

35.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: FYB is unprofitable, but has reduced losses over the past 5 years at a rate of 35% per year.

Accelerating Growth: Unable to compare FYB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: FYB has a negative Return on Equity (-2.38%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: FYB is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: FYB is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Formycon's financial position?


Financial Position Analysis

Short Term Liabilities: FYB's short term assets (€28.3M) exceeds its short term liabilities (€3.5M)

Long Term Liabilities: FYB's short term assets (28.3M) exceeds its long term liabilities (702.1K)


Debt to Equity History and Analysis

Debt Level: FYB is debt free.

Reducing Debt: FYB had no debt 5 years ago.


Balance Sheet

Inventory Level: FYB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if FYB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if FYB has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FYB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Formycon's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FYB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Formycon's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average board tenure


CEO

Carsten Brockmeyer 0

6.5yrs

Tenure

0

Dr. Carsten Brockmeyer, PhD, has been Chief Executive Officer and Member of Executive Board at Formycon AG since April 16, 2013 and served as its Chairman of Executive Board. Dr. Brockmeyer has more than 2 ...


Board Age and Tenure

4.6yrs

Average Tenure

Experienced Board: FYB's board of directors are considered experienced (4.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Nicolas Combé

    Co-Founder

    • Tenure: 0yrs
  • Friedrich-Wilhelm Steinweg

    Co-Founder

    • Tenure: 0yrs
  • Carsten Brockmeyer

    CEO & Member of Executive Board

    • Tenure: 6.5yrs
  • Stefan Glombitza (54yo)

    COO & Member of Executive Board

    • Tenure: 3yrs

Board Members

  • Bernhard Hampl (69yo)

    Member of Advisory Board

    • Tenure: 5.6yrs
  • Gerhard Schaefer

    Member of Advisory Board

    • Tenure: 5.9yrs
  • Hermann Vogt

    Deputy Chairman of Supervisory Board

    • Tenure: 0yrs
  • Olaf Stiller (42yo)

    Chairman of Supervisory Board

    • Tenure: 0yrs
  • Peter Wendeln

    Member of Supervisory Board

    • Tenure: 0yrs
  • Johannes Buchner

    Member of Advisory Board

    • Tenure: 3.7yrs
  • Thomas Siklosi

    Member of Advisory Board

    • Tenure: 1.2yrs

Company Information

Formycon AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Formycon AG
  • Ticker: FYB
  • Exchange: XTRA
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €342.000m
  • Shares outstanding: 10.00m
  • Website: https://www.formycon.com

Number of Employees


Location

  • Formycon AG
  • Fraunhoferstrasse 15
  • Martinsried
  • Planegg
  • Bavaria
  • 82152
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FYBDB (Deutsche Boerse AG)YesBearer SharesDEEURDec 2010
FYBXTRA (XETRA Trading Platform)YesBearer SharesDEEURDec 2010
0W4NLSE (London Stock Exchange)YesBearer SharesGBEURDec 2010
FYBDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURDec 2010
FYBETLX (Eurotlx)YesBearer SharesITEURDec 2010

Biography

Formycon AG engages in the development and marketing of biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovasc ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 21:20
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.